Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
06990
Company Profile
Business description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Contact
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park
Wenjiang
Sichuan
Chengdu
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,045
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,816.94 | 44.49 | 0.57% |
| DAX 40 | 22,680.04 | 117.16 | 0.52% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,176.45 | 48.49 | 0.48% |
| HKSE | 25,346.36 | 558.22 | 2.25% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,474.95 | 2,411.23 | 4.72% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.43 | 56.57 | 1.45% |